Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $310.78.

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...

THOUSAND OAKS, Calif., Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best drug stocks to buy now.

US drug major Amgen on Monday announced the opening of its new technology and innovation site in Hyderabad. The company said it plans to invest $200 million through 2025, with additional ...